It’s been a busy quarter for UTEST company TrendMD. Fresh off their participation in Ycombinator’s Winter 2016 cohort, which was covered in TechCrunch, the company has announced partnerships with HighWire and Integra.
TrendMD, a Canadian start-up company, is a content recommendation engine for scholarly publishers. They work with over 2,000 medical journals by organizing and tailoring information to the appropriate audiences. This functionality creates several opportunities for various researchers to promote their research and clinical practices in their respective fields.
TrendMD launched through ...
Company initiating two new clinical trials for recurrent and newly diagnosed malignant gliomas
TORONTO and SAN DIEGO, (May 03, 2016) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in the development of marizomib for the potential treatment of malignant gliomas.
The two companies will collaborate on a Phase 2 study using marizomib (MRZ) as monotherapy in recurrent glioblastoma, as well as a Phase ...
"Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.," Leonard Zahr wrote in a feature article on Xagenic's product development progress for BioTuesdays on April 19, 2016.
Xagenic was founded by University of Toronto Professor Shana Kelley in partnership with MaRS Innovation and U of T's Innovations & Partnerships Office in 2010. The company ...
Results for results in docetaxel-resistant prostate cancer models presented at the American Association for Cancer Research (AACR) Conference
TORONTO and SAN DIEGO (April 18, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, and the Ontario Institute for Cancer Research (OICR), today announced positive results from a preclinical study of their CBZed-Nano™ (cabazitaxel cellulose nanoparticle) product in docetaxel-resistant prostate cancer mouse models. Preliminary results also showed that the nanoparticles accumulate in intracranial brain ...
Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017
HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation.
This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today.
VICE featured XOR's life-saving lung transplant technology ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc.
This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on decades of diabetes research by renowned University of Toronto (U of T) professor, Dr. Mladen Vranic.
Zucara Therapeutics will attend Does of the Valley in February 2016. The ...
TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.
Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ...
MaRS Innovation's "model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding," writes Thierry Heles in, "MaRS Innovation: A Unique Model for Tech Transfer," for Global University Venturing.
This feature was also covered in Techopia.
The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.
Here's an excerpt exploring the range of MI's portfolio and Hofstein's strategy for addressing technologies emerging in new ...